Loading news...
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago.
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026 Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced it has entered into a subscription agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $85 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about Tuesday, March 10, 2026, subject to satisfaction of customary closing conditions.
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, three have given a buy recommendation and one has issued
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar's presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET.
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Korro Bio (NASDAQ: KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing therapeutic candidate the company believes could provide a new approach to controlling elevated blood ammonia in urea cycle disorders (UCD) and hepatic encephalopathy (HE). Management and invited speakers emphasized the clinical burden of hyperammonemia, limitations of current
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m.
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) fell 5.9% during trading on Monday. The company traded as low as $8.62 and last traded at $8.94. 183,664 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 178,249 shares. The stock had previously closed at $9.50.
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference.
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have been given a consensus rating of "Hold" by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating
Korro Bio, Inc. (NASDAQ: KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $1.92 per share versus the Zacks Consensus Estimate of a loss of $2.61. This compares to a loss of $2.26 per share a year ago.
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional protein following a single administration — Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026 — Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia — Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by implementing a strategic restructuring CAMBRIDGE, Mass.
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has been assigned a consensus rating of "Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company.
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: